



January 31, 2014

Company Name	3 - D M a t r i x , L t d .
A d d r e s s	3-2-4, Kojimachi, Chiyoda, Tokyo
P r e s i d e n t	Kentaro Takamura
Code Number	7777
C o n t a c t	Director Tomoyuki Arai
T E L	+81 3 (3511)3440

**MIT and 3-D Matrix, Inc. Files Patent Infringement Complaint
Against Menicon Co. Ltd. and B-Bridge International Inc.**

The company hereby announces that our consolidated subsidiary in the United States, 3-D Matrix, Inc. and patent owner Massachusetts Institute of Technology (MIT) have filed a patent infringement complaint on behalf of itself with the Federal District Court in Massachusetts against Menicon Co. Ltd. (Menicon) and B-Bridge International Inc. (B-Bridge). 3-D Matrix, Inc. has also challenged the validity of a patent owned by Menicon.

The complaint alleges that Menicon's PanaceaGel™ infringes claims of two patents that relate to self-assembling peptides and methods: U.S. Patent No. 5,670,483, titled "Stable Macroscopic Membranes Formed by Self-Assembly of Amphiphilic Peptides and Uses Therefor," and U.S. Patent No. 5,955,343, titled "Stable Macroscopic Membranes Formed by Self-Assembly of Amphiphilic Peptides and Uses Therefor." The district court complaint requests an injunction to prevent future infringement by Menicon and B-Bridge and monetary damages for the ongoing infringement.

3-D Matrix, Inc. has also filed a request for re-examination of a Menicon patent with the United States Patent and Trademark Office based on Menicon's omission in recognizing MIT professor and 3-D Matrix, Inc. founder Shuguang Zhang as an inventor of the self-assembling peptides and methods of use claimed in a Menicon patent that supports PanaceaGel™. The challenged patent is U.S. Patent No. 8,299,032. 3-D Matrix, Inc. has filed a patent application with the United States Patent and Trademark Office to address the omission by Menicon.

This patent infringement complaint serves as evidence that we will protect and enforce our intellectual property rights. Our founder, Professor Zhang, is a pioneer in the self-assembling peptide field and his extensive work should be recognized and protected.

The company continues to defend the patent portfolio of our self-assembling peptides to prevent unlawful competitive practices.

The company does not expect significant impact on our earnings forecast and "mid-term business plan" from this complaint at the moment.